**Title page**

**Platelets compensate for poor thrombin generation in type 3 von Willebrand disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Peak thrombin in PPP | ETP in PPP | Peak thrombin in PRP | ETP in PRP |
| FVIII | **r=0.77****p=0.023** | r=0.33p=0.38  | r=0.69p=0.19  | r=0.60p=0.19  |
| VWF:GPIbM | r=0.53p=0.19  | r=0.03p=0.96  | r=0.37p=0.19  | r=0.37p= 0.41  |
| VWF:Ag | r=0.50p=0.17  | r=0.16p=.69  | r=0.69p=0.09  | r=0.66p=0.48  |
| VWF:CB | **r=0.81****p=0.016** | r=0.48p=0.19  | r=0.55p=0.20  | p=0.65p=0.23  |
| ADAMTS-13 | r=0.55p=0.13 | r=0.37p=0.37 | r=0.66p=0.059 | r=0.68p=0.11 |
| TFPI total/free | r=-0.40/-0.083p=0.29 / 0.84 | r=-0.77/-0.083p=0.067/0.071 | r=-0.071/-0.30p=0.31/0.91 | r=-0.38/-0.05p= p=0.39/0.91 |
| PS | r=0.27p=0.49 | r=0.48p=0.19 | r=0.13p=0.74 | r=0.43p=0.35 |
| F1+2 | r=-0.53p=0.15 | r=-0.62p=0.086 | r=-0.63p=0.076 | r=-0.32p=0.49 |
| P-selectin % (ADP 1 µM) | r=-0.45p=0.26 | r=-0.52p=0.27 | r=-0.29p=0.50 | r=-0.31p=0.56 |
| P-selectin % (ADP 2 µM) | r=-0.31p=0.46 | r=-0.52p=0.46 | r=-0.29p=0.88 | r=-0.31p=0.91 |
| P-selectin % (ADP 5 µM) | r=-0.33p=0.43 | r=-0.33p=0.43 | r=-0.14p=0.75 | r=-0.089p=0.91 |
| Annexin V % (CRP 0.5 mg/mL) | r=-0.43p=0.30 | r=-0.21p=0.61 | r=-0.24p=0.58 | r=-0.26p=0.66 |
| Annexin V % (CRP 7.5 mg/mL) | r=-0.41p=0.33 | r=-0.29p=0.50 | r=-0.17p=0.70 | r=-0.20p=0.71 |
| Annexin V % (CRP 15 mg/mL) | r=-0.41p=0.33 | r=-0.29p=0.50 | r=-0.17p=0.70 | r=-0.20p=0.71 |
| BAT | r=-0.18p=0.65 | r=-0.38p=0.32 | r=-0.05p=0.90 | r=0.25p=0.59 |

**Supplementary Table 1.** TG parameters peak thrombin and ETP in association to FVIII,VWF, ADAMTS-13, TFPI (free and total), PS, F1+2, flow cytometry analysis and BAT by Spearman’s correlation. Only peak thrombin in PPP showed correlation to FVII and VWF:CB. None of the TG parameters showed association to ADAMTS-13, TFPI or platelet activation status in flow cytometry.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **EXTEM****CT**38-79 s | **EXTEM****CFT** 34-159 s | **EXTEM**α 63-83 ° | **EXTEM****MCF** 50-72 mm | **INTEM****CT** 100-240 s | **INTEM****CFT** 30-110 s | **INTEM****α**70-83 ° | **INTEM****MCF** 50-72 mm | **FIBTEM****MCF** 9-25 mm |
| Alln=9 | **49**44-52 | **69**51-106 | **79**71-85 | **68**62-72 | **186**162-207 | **65**41-105 | **77**70-81 | **70**61-73 | **21**12-27 |
| PREn=6 | **49**47-52 | **69**51-106 | **78**71-82 | **69**62-72 | **184**172-207 | **68**41-105 | **76**70-81 | **69**61-73 | **20**12-27 |
| POSTn=6 | **48**43-62 | **84**51-136 | **78**64-83 | **68**62-72 | **190**160-235 | **77**65-81 | **75**71-80 | **67**63-73 | **19**13-26 |

**Supplementary Table 2.** Thromboelastometry (ROTEM) (median and range) in all patients, also given before and after treatment. No significant change was detected between pre and post samples in any parameter (p>0.05). Reference ranges provided by the manufacturer given in the top column.